Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populationsArticle Published on 2022-09-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단, [키워드] Advax-CpG adverse event antibody Cellular immune response composed conducted COVID-19 COVID-19 vaccine dose double-blind fatigue geometric mean concentration humoral incidence injection site pain Mild outcome participant phase Phase 2 phase 2 trial Placebo placebo-controlled Population primary immunogenicity Protein Randomized randomized placebo-controlled trial receive Safety safety profile SARS-CoV-2 SARS-CoV-2 spike protein second dose Serious Adverse Event Seroconversion seroconversion rate seronegative seropositive SpikoGen subunit subunit protein vaccine. the placebo group vaccination Vaccine Volunteer were recorded [DOI] 10.1016/j.cmi.2022.04.004 PMC 바로가기
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of ConcernArticle Published on 2022-08-302022-11-15 Journal: mBio [Category] SARS, 변종, 진단, [키워드] active against addition Adults anti-SARS-CoV-2 anti-SARS-CoV-2 immune responses approved booster booster dose Brazil CD4 cellular Chilean China clinical trial concern CoronaVac COVID-19 Delta dose doses Emergency use healthy healthy volunteers homologous humoral immune response Immunity immunized IMPROVE inactivated Inactivated vaccine increase interferon neutralizing antibody not significantly different omicron phase phase III clinical trial. previous study reached reduced reported SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2-specific T cell second dose secretion shown significant increase significantly T cell T cell activation T cell response the vaccine these cell Turkey vaccination schedule Vaccine variants of concern VoC VOCs were assessed WHO World Health Organization [DOI] 10.1128/mbio.01423-22 PMC 바로가기
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load코로나19 고위험 보행 환자를 대상으로 한 밤라니비맙과 에테세비맙의 무작위 위약 대조 임상 시험 및 지속적으로 높은 바이러스 부하의 예후 가치 검증Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age ambulatory ambulatory patient ambulatory patients antibody treatment applicability bamlanivimab baseline characterized clinical clinical status Cohort confidence interval coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 test Day death determine etesevimab expand first positive greater high risk Hospitalization infused Interim analyses interim analysis intravenously investigated load lower dose median median age Mild-to-moderate NCT04427501 occurred optimal dose outcome Patient persistently high viral load. phase Placebo placebo group receiving reduction in respiratory risk factor SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 Support the placebo group These data those receiving placebo Treatment Trial validation value variant Viral Viral load [DOI] 10.1093/cid/ciab912 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial6세 이상의 건강한 참가자를 대상으로 한 상동 프라임-부스트 요법을 사용한 재조합 아데노바이러스 5형 벡터 코로나바이러스 질병 2019(COVID-19) 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 2b상 시험Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] 임상, 진단, 치료기술, [키워드] Ad5-vectored COVID-19 vaccine Adenovirus adenovirus type-5-vectored COVID-19 vaccine Adults Adverse adverse events antibody Antibody Response boost children clinical Cohort coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose double-blind elicited ELISA enrolled enzyme enzyme-linked immunosorbent assay event geometric mean geometric mean titer geometric mean titers GMT GMTs healthy homologous homologous prime immune response immune responses immunogenicity increasing age MIN neutralizing antibody participant phase phase 2b trial. Placebo placebo-controlled trial prime-boost regimen pseudovirus neutralizing antibody Randomized RBD receiving Receptor binding domain recombinant recombinant adenovirus robust Safe Safety SARS-CoV-2 single dose tolerable Trial vaccination Vaccine Viral viral particle [DOI] 10.1093/cid/ciab845 PMC 바로가기 [Article Type] Randomized Controlled Trial
A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial – implications for therapeutic immune modulationResearch article Published on 2022-08-182022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, 변종, 임상, [키워드] 1:1 Activation Adaptive immune response addition adverse event ARCADIA assigned AZD1656 Clinical improvement clinical trial Complete COVID-19 cytokine Czech Republic Day death decrease diabetes diabetic patient diabetic patients dose double-blind duration of hospitalisation Efficacy Excalibur False positive finding Full Analysis Set funding Glucokinase activator group homeostatic hospital hospital discharge hospitalised identify immune Immune cell immune modulation immune response Immunochemistry immunomodulatory effect Immunophenotyping implication indicated Innovation investigated involved less Medicine multicentre nine no difference Patient phase Phase 2 Placebo placebo-controlled placebo-controlled clinical trial primary analysis primary endpoint pro-inflammatory randomised Randomly receive recruited reduction in Registered regulatory T cells required risk Romania SARS-CoV-2 screened statistically significant difference suggested Tablet the placebo group therapeutic therapeutic effect treated Treatment treatment allocation Tregs Trial usual care with COVID-19 [DOI] 10.1016/j.eclinm.2022.101604 [Article Type] Research article
PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19PIKfyve 특정 억제제는 시험관 내에서 여러 코로나바이러스의 복제를 제한하지만 COVID-19의 쥐 모델에서는 제한하지 않습니다Article Published on 2022-08-122022-09-11 Journal: Communications Biology [Category] 비임상, 임상, 치료기술, 치료법, 치료제, [키워드] antiviral activity apilimod approved authorization cell line claimed Community Compound COVID-19 COVID-19 pandemic disease Efficacy effort Emergency Emergency use authorization Healthcare systems human coronaviruses in vitro inhibitor Medical countermeasures multiple coronaviruses murine model nucleoside pandemic Paxlovid phase PIKfyve PIKfyve inhibitor prophylactically Protease inhibitor Remdesivir Replication Research restrict small molecule tested the United State therapeutic Therapeutics these compound these compounds Treatment Trial trials United States Vaccine writing [DOI] 10.1038/s42003-022-03766-2 PMC 바로가기 [Article Type] Article
Inactivated vaccine Covaxin/BBV152: A systematic review비활성화 백신 Covaxin/BBV152: 체계적인 검토Article Published on 2022-08-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, [키워드] adjusted Administered adverse event Aluminium aluminium hydroxide Antigen AZD1222 BBV152 Beta Bharat binding antibody clinical trial Combination Corona Covaxin Coverage Covishield Delta Delta variants doses Effectiveness Efficacy Evidence evidence of fatality gel heterologous prime-boost hydroxide immunogenicity inactivated Inactivated vaccine India infected individual Local Neutralizing omicron Omicron variant pandemic phase Phase I Phase III trials provided Quinolin reported safety profile Safety. SARS-CoV-2 pandemic screened searched second dose Serious Adverse Event Serious Adverse Events severe COVID-19 surpassed symptomatic infection systematic review systemic adverse events T cell T cell response T cell responses the SARS-CoV-2 Trial vaccination Vaccine Vaccines variant variants virus Zeneca [DOI] 10.3389/fimmu.2022.863162 PMC 바로가기 [Article Type] Article
The impact of clinical pharmacist implemented education on the incidence of prescribing errors in COVID-19 patientsResearch article Published on 2022-08-012022-10-05 Journal: Saudi Pharmaceutical Journal : SPJ [Category] 임상, 진단, 치료제, [키워드] clinical Clinical pharmacist conditions conducted COVID-19 COVID-19 pandemic COVID-19 patient education evaluate followed by hospital hospitals incidence Intervention medication patients with COVID-19 phase Physicians Prescribing errors reduce reduced Result retrospective significantly [DOI] 10.1016/j.jsps.2022.06.007 [Article Type] Research article
Accuracy of 2 Rapid Antigen Tests During 3 Phases of SARS-CoV-2 VariantsArticle Published on 2022-08-012022-11-15 Journal: JAMA Network Open [Category] SARS, 변종, 치료기술, [키워드] 95% CI Accuracy age Alter Antigen B.1.617.2 Card clinical testing collected COVID-19 COVID-19 testing COVID-19 vaccination Culture cycle threshold Delta demonstrated diagnostic diagnostic sensitivity diagnostic tests enrolled female infectious dose Intervention IQR King limit of detection median nasal swab no significant difference nucleocapsid antigen Older omicron outcome participant phase positive ranged Rapid rapid antigen test Rapid diagnostic test reduce reported RT-PCR RT-PCR testing SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 transmission SARS-CoV-2 variants sequence variation specificity specimen Symptom symptom onset Test tested The diagnostic sensitivity tissue USA-WA1/2020 variant variants viral genome Viral load Washington wild-type with COVID-19 [DOI] 10.1001/jamanetworkopen.2022.28143 PMC 바로가기
Plant formulation ATRICOV 452 in improving the level of COVID-19 specific inflammatory markers in patientsResearch article Published on 2022-08-012022-10-05 Journal: Contemporary Clinical Trials Communications [Category] 바이오마커, 신약개발, 임상, [키워드] adverse event assigned Care clinical trial conducted COVID-19 COVID-19 patient CTRI determine dose dropped effective Efficacy evaluate faster Frequency healthcare healthy healthy volunteer hospital Human Importance IMPROVE Inflammatory marker inflammatory markers objective organ system oxygen Patient phase Phase 1 Phase 2 phase 2 trial Placebo plant Plant formulation (ATRICOV 452) primary analysis population randomization receive reduce Registration Result Safe setting Standard of care Support therapeutic intervention Tolerability treatment group Trial Volunteer [DOI] 10.1016/j.conctc.2022.100961 [Article Type] Research article